RiMO-301 enhances the efficacy of X-ray radiotherapy via the radiotherapy-radiodynamic therapy (RT-RDT) mode of action.
The Phase 1 study is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. The primary objectives in the study include determining maximum tolerated dose, pharmacokinetics and preliminary anti-tumor activity of RiMO-301.
Privately held RiMO Therapeutics aims to address unmet medical needs and improve patient care. Its nMOF technology is in-licensed from the University of Chicago with worldwide rights in development and commercialisation.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval